If you had a ๐ง๐๐ฎ๐ซ๐จ๐๐ง๐๐จ๐๐ซ๐ข๐ง๐ ๐ญ๐ฎ๐ฆ๐จ๐ซ ๐ข๐ง ๐ฒ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐จ๐ฆ๐๐๐ก, ๐ฌ๐ฆ๐๐ฅ๐ฅ ๐ข๐ง๐ญ๐๐ฌ๐ญ๐ข๐ง๐, ๐๐ฉ๐ฉ๐๐ง๐๐ข๐ฑ, ๐๐จ๐ฅ๐จ๐ง, ๐ฉ๐๐ง๐๐ซ๐๐๐ฌ, ๐ฅ๐ฎ๐ง๐ ๐ฌ, ๐๐๐ซ๐๐ง๐๐ฅ ๐ ๐ฅ๐๐ง๐๐ฌ, ๐ญ๐ก๐ฒ๐ซ๐จ๐ข๐, ๐ฉ๐ข๐ญ๐ฎ๐ข๐ญ๐๐ซ๐ฒ, ๐ซ๐๐๐ญ๐ฎ๐ฆ, ๐๐ซ๐๐๐ฌ๐ญ, ๐จ๐ซ ๐ฉ๐ซ๐จ๐ฌ๐ญ๐๐ญ๐, ๐ฐ๐จ๐ฎ๐ฅ๐ ๐ฒ๐จ๐ฎ ๐ฐ๐๐ง๐ญ ๐ญ๐จ ๐ญ๐ซ๐ฒ ๐ ๐ซ๐๐๐ข๐จ๐๐๐ญ๐ข๐ฏ๐ ๐๐ซ๐ฎ๐ ย as (a small) part of the treatment?
The emerging clinical dataset highlights excellent short-term tolerability for 212Pb-TAT, with adverse events primarily consisting of low-grade nausea, fatigue, and manageable lymphocytopenia.3,17,18,21 However, long-term toxicities are typically delayed and insidious. The pituitary gland is the prime organ at risk due to high SSTR2 expression in the anterior pituitary, with diagnostic [68Ga]Ga-DOTATATE PET/CT consistently showing uptake in the sella turcica. While beta-PRRT carries an โ 8% risk of delayed pituitary dysfunction over 5โ10 years,4 the higher relative biological effectiveness (RBE) of alpha particles could substantially increase this risk. Preclinical models provide direct evidence of alpha particle-induced endocrine disruption.
Long-term radiotoxicity studies with [212Pb]Pb-TCMC (1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane)-rituximab in murine models of Non-Hodgkin lymphoma demonstrate that renal toxicity may emerge months after treatment. Quelven et al (2025) observed significant increases in urea and creatinine at 4โ6 months post-therapy, with histopathologically confirmed renal damage.26 Notably, toxicity was reduced by optimizing specific activity, suggesting that careful dose optimization and extended follow-up are essential for 212Pb-based therapies.
Therapy-related myeloid neoplasms/acute myeloid leukemia (t-MDS/AML) occur in 2%โ3% of beta-PRRT patients with latency of several years7โa risk plausibly heightened with alpha-emitters due to potent energy deposition in hematopoietic stem cells.4,5 The bystander effect expands the potential โat-riskโ tissue volume beyond cells with direct radiopharmaceutical uptake, meaning healthy cells adjacent to targeted cells may suffer collateral damage via intercellular signaling.14
First-in-human phase 0 studies of prostate-specific membrane antigen (PSMA)-targeted 212Pb ligands confirm safety and feasibility in heavily pretreated populations. While therapeutic efficacy was not expected at microdose levels, the favorable safety profile supports further dose-escalation trials.
An unexpected safety advantage of 212Pb-labeled radiopharmaceuticals is their inherent antimicrobial potency. Studies with [212Pb]Pb-dotamtate demonstrated a โฅ 6-log reduction in colony-forming units for microorganisms, including S. aureus and C. albicans, within 6 hours of exposure, at absorbed doses below 1.01 kGy.28 This โself-sterilizingโ property adds an additional layer of pharmaceutical safety, reducing the risk of microbial contamination in drug product vials.
Activate to view larger image,
Posted in